干酪乳杆菌JH23代谢产物对单胺氧化酶的抑制作用

本文旨在分离干酪乳杆菌JH-23中具有抑制单胺氧化酶(MAO)活性的代谢产物.用乙酸乙酯对干酪乳杆菌JH23发酵液进行抽提,得到的脂溶性成分和水溶性成分在一定浓度范围内对MAO的抑制活性呈较好的量效关系.其中,脂溶性成分对MAO-A、MAO-B抑制作用的IC50分别为1.97和5.67 mg/mL;水溶性成分对MAO-A、MAO-B抑制作用的IC50分别为1.59和4.83 mg/mL.抑制特征曲线显示,两者对MAO-A与MAO-B的抑制作用均呈竞争性抑制.从水溶性成分中分离得到的活性组分W1对MAO-A、MAO-B抑制作用的IC50分别为0.33和1.13 mg/mL.通过进一步分离,以及红外和质谱分析,确定了组分W1中具有较强MAO抑制作用的物质为琥珀酸.     

归芪多糖延缓衰老作用的研究

本文研究了归芪多糖对衰老小鼠的抗衰老作用。将50只小鼠分为5组,除正常对照组外其余各组均采用D-半乳糖(0.5 g·kg-1)皮下注射建立衰老小鼠模型,以不同剂量的归芪多糖(1 g/kg和0.5 g/kg)给小鼠连续灌胃42 d后,测定其血清中过氧化氢(H2O2)和皮肤组织中羟脯氨酸(Hyp)含量、大脑中单胺氧化酶(MAO)、肝组织中谷胱甘肽-过氧化物酶(GSH-PX)和黄嘌呤氧化酶(XOD)的活性。结果显示,归芪多糖能明显抑制小鼠血清H2O2含量、肝组织XOD和大脑MAO的活性(P<0.01);显著提高肝组织中GSH-PX的活性和皮肤组织中Hyp的含量(P<0.01)。证明归芪多糖可能通过降低衰老小鼠血清H2O2的含量、肝组织XOD和大脑MAO的活性,以及提高肝组织GSH-PX的活性和皮肤组织中Hyp的含量的机制起到一定的抗衰老作用。     

黄芪多糖与枸杞多糖联用对小鼠肝组织损伤的保护作用

探究黄芪多糖与枸杞多糖对四氯化碳(CCl_4)所致小鼠急性肝损伤的协同保护作用。采用CCl_4诱导小鼠急性肝损伤,动物处死后取血液测定血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)活性,取肝脏计算肝指数并制备肝匀浆测定其中谷胱甘肽(GSH)活力、丙二醛(MDA)含量,并对小鼠肝脏进行组织切片观察,评价黄芪多糖与枸杞多糖联用对小鼠肝组织的保护效果。实验显示,黄芪多糖与枸杞多糖各配比(LBP 50 mg/kg+APS 100,LBP 70 mg/kg+APS 400,LBP 350 mg/kg+APS 800)均能显著抑制CCl_4急性肝损伤所引起的MDA含量、肝脏指数、ALT和AST活性的升高(p0.05),有效地提高肝脏中GSH的含量,减轻小鼠的肝组织损伤程度。本研究表明黄芪多糖与枸杞多糖联用对CCl_4诱导的小鼠急性肝损伤有明显的保护作用。     

小鼠组织中过氧化氢酶的活性与年龄的关系

为观察小鼠组织中过氧化氢酶的活性与年龄的关系,采用高锰酸钾滴定法测定不同年龄(1、4、18月龄)小鼠肝、肾、肺、心、脾、胃、脑组织中过氧化氢酶的活性。结果显示:小鼠过氧化氢酶在不同组织中活性不同,活性高低顺序基本表现为:肝>肾>肺>心、脾、胃>脑;小鼠肺、心、脾、胃、脑各组织中过氧化氢酶的活性在1～4月龄间随年龄增加而增加,在4～18月龄间随年龄增加而降低;小鼠肝、肾组织中过氧化氢酶的活性在1～4月龄间与年龄相关性不显著,在4～18月龄间随年龄增加而降低。结果表明,小鼠肝、肾、肺、心、脾、胃、脑等组织中过氧化氢酶的活性随年龄变化而变化,机体过氧化氢酶活性的降低与机体衰老密切相关。     

蕨菜黄酮对小鼠体内丙二醛含量的影响

采用硫代巴比妥酸法(TBA法)测定小鼠血清和肝组织中丙二醛(malondialdehyde,MDA)的相对含量.结果表明,蕨菜黄酮可降低小鼠血清及肝组织中MDA含量.对于血清,随着饲喂的蕨菜黄酮量的增加,MDA相对含量降低的程度越显著,150mg/kg组与300mg/kg组相比,MDA相对含量差异达到极显著水平(P＜0.01);对于肝组织,随着蕨菜黄酮量的增加,MDA相对含量逐渐降低,但当蕨菜黄酮量达到一定值(150mg/kg)后,再继续加入蕨菜黄酮量,则对MDA相对含量的影响与150mg/kg组相比无显著差异.说明在本实验条件下,饲喂蕨菜黄酮有明显改善小鼠机体代谢合成,具有清除体内氧自由基功能以及增强机体抗氧化功能等保健作用.     

酵母类金属硫蛋白抗氧化作用的研究

酿酒酵母（Saccharomycescerevisiae）YBD101菌株的类金属硫蛋白能清除羟基自由基。含类金属硫蛋白的活性的干酵母饲喂7个半月龄昆明小鼠,可提高肝中SOD活性（p＜0．01）,降低LPO含量（p＜0．01）,对脑中MAO－B活性有一定抑制作用（p＜0．01）,对肝中MAO－B活性几乎不抑制。含类Cu－MT活性干酵母对上述衰老有关三项生化指标的作用,与免肝Zn-MT纯品效果一致。提示酵母菌类Cu－MT在预防衰老和保护人体健康方面有良好的应用前景。     

青年和老年小鼠脑糖原及其代谢的差异

目的:比较青年小鼠和老年小鼠不同脑区糖原及其代谢的差异,为后续相关研究奠定基础。方法:分别取雄性C57BL/6J青年小鼠(8周龄)和老年小鼠(18月龄)皮层、海马、纹状体三个脑区脑组织,通过糖原定量试剂盒检测糖原含量,通过Western Blot检测糖原代谢相关酶(包括糖原合成、糖原分解、葡萄糖转运、乳酸转运相关酶类)的表达水平。结果:与青年小鼠相比,老年小鼠皮层、纹状体糖原含量明显上升,但海马的糖原含量无明显变化。在糖原合成代谢的关键酶中,糖原合成酶在老年小鼠皮层、纹状体的表达水平明显升高,而海马区则无明显差异;糖原分支酶在老年小鼠皮层的表达水平有所下降,在海马和纹状体则无明显变化。在糖原分解代谢的关键酶中,老年小鼠的糖原磷酸化酶在皮层、海马和纹状体均明显升高,而糖原脱支酶在上述脑区则无明显变化。葡萄糖转运体1的表达水平在老年小鼠与青年小鼠各脑区无显著差异。在单羧酸转运体中,老年小鼠单羧酸转运体1在各脑区均明显上升,单羧酸转运体4在皮层明显升高,其余脑区则无明显差异。结论:老年小鼠脑内糖原含量总体上较青年小鼠高,老年小鼠脑糖原代谢通路相关酶的表达与青年小鼠存在明显差异,且不同脑区之间存在异质性。     

香水莲花总提取物对小鼠急性酒精肝损伤的实验研究

目的:观察香水莲花提取物对酒精所致小鼠急性化学损伤的保护作用。方法:雄性昆明种小鼠70只,随机分为正常对照组、急性酒精肝损伤模型组、水飞蓟素阳性对照组(46.7 mg/kg)以及香水莲花低、中、高剂量组(120、180、240 mg/kg)共6组,检测肝组织甘油三酯(TG)、丙二醛(MDA)和还原型谷胱甘肽(GSH)含量,称量体重和肝脏重量。结果:香水莲花总提取物能够抑制急性酒精肝损伤小鼠肝组织的TG、MDA含量升高(P0.05),增加GSH含量(P0.05)。结论:香水莲花总提取物对急性酒精肝损伤有明显的保护作用。     

鱼皮低聚肽对小鼠急性酒精性肝损伤的保护作用

目的：探究鱼皮低聚肽（FOPs）对酒精损伤小鼠肝功能及糖脂代谢的影响。方法：将60只KM小鼠作为研究对象分为空白组（蒸馏水）、模型组（蒸馏水）、阳性组（水飞蓟素,200 mg/kg BW）、FOPs组（250、500、1 000 mg/kg BW）。实验第33天灌胃制ALD模型。对小鼠各相关联指标（肝功能、血糖、血脂和氧化）的含量和活性进行检测,并量化分析肝组织的脂滴情况进行。结果：FOPs氨基酸的成分组成甘氨酸（Gly）含量最高,其中90.61%均为低于1 000 U的小肽;FOPs各剂量组小鼠血清的肝功能指标AST、ALT活力和血脂TG、TC含量显著降低（P＜0.05）,250、500 mg/kg BW FOPs的TC含量略低于阳性组;FOPs 各剂量组与模型组比较,肝脏合成蛋白指标TP、ALB含量随浓度的增加而升高,FOPs（250、1 000 mg/kg BW）组血糖GLU含量则明显增高（P<0.05）;250、1 000 mg/kg BW剂量组肝组织过氧化指标MDA含量显著降低（P＜0.05）,FOPs各剂量组肝组织抗氧化指标GSH活性明显增高,甚至优于空白组,与模型组相比差异显著（P<0.05）。小鼠肝组织油红O染色表明,FOPs缓解小鼠急性酒精肝细胞损伤的脂肪病变程度显著（P<0.05）。结论：FOPs在急性乙醇小鼠的肝功能损伤和糖脂代谢方面方面具有良好的保护功能。     

芍药苷减轻四氯化碳诱导的急性肝损伤

为研究芍药苷对四氯化碳(CCl_4)诱导的急性肝损伤的保护作用及相关机制。将36只健康雄性C57BL/J小鼠随机分成6组:空白组,芍药苷对照组,CCl_4模型组(0.1%,20 mL/kg),高、中、低剂量芍药苷+CCl_4组(10 mg/kg,30 mg/kg,100 mg/kg),每组6只。24 h后眼球取血收集血清,测定丙氨酸氨基转移酶(ALT),天门冬氨酸氨基转移酶(AST)活性。用苏木精-伊红(HE)染色,观察肝脏的组织学改变;试剂盒测定肝组织中SOD、GSH-PX、CAT的活性及MDA和GSH含量;ELISA法检测血清中TNF-α、IL-6含量;试剂盒检测小鼠肝组织中Caspase-3的活性;q RT-PCR检测肝组织中HO-1 mRNA的表达。实验发现PAE降低小鼠血清ALT、AST水平,改善肝脏的病理形态;芍药苷抑制CCl_4诱导氧化应激,升高肝组织HO-1 mRNA水平;降低TNF-α、IL-6含量;芍药苷减低肝组织中Caspase-3活性,减少肝细胞凋亡。由此可知,芍药苷可保护CCl_4诱导的急性肝细胞损伤,该保护作用可能与抑制脂质过氧化,减少促炎细胞因子产生,减少肝细胞凋亡,促进抗氧化蛋白表达有关。     

Monoamine Oxidase-Inhibiting Properties of SR 95191, a New Pyridazine Derivative, in the Rat: Evidence for Selective and Reversible Inhibition of Monoamine Oxidase Type A In Vivo but Not In Vitro

In rodents, SR 95191 [3-(2-morpholinoethylamino)-4-cyano-6-phenylpyridazine] has been shown to be active in animal models of depression. The profile of activity of SR 95191 suggests that the compound is a selective and short-acting type A monoamine oxidase (MAO) inhibitor (MAOI) in vivo. In the present study, the interaction of SR 95191 with MAO-A and MAO-B activity was further examined in vivo and in vitro. In brain, liver, and duodenum of pretreated rats, SR 95191 selectively inhibited MAO-A (ED50 = 3-5 mg/kg, p.o.), whereas MAO-B was only weakly inhibited for doses as high as 300 mg/kg, p.o. In vivo, SR 95191 (1-100 mg/kg, p.o.) antagonized, in a dose-dependent fashion, the irreversible inhibition of brain and liver MAO-A induced by phenelzine. Finally, dopamine and 5-hydroxytryptamine depleted from their striatal stores by tetrabenazine were able to displace SR 95191 from the active site of MAO-A. However, ex vivo, kinetic studies showed that the inhibitory effect of SR 95191 (1-10 mg/kg) towards MAO-A was noncompetitive and was unchanged after dilution or dialysis. In vitro, the inhibition of brain MAO-A, but not MAO-B, by SR 95191 was time dependent, with a 19-fold decrease in the IC50 values being observed over a 30-min incubation period (140 to 7.5 microM). At this time, the SR 95191-induced inhibition of MAO-A was not removed by repeated washings. When the reaction was started by adding the homogenate without prior preincubation with SR 95191, the inhibition of brain MAO-A was fully competitive (Ki = 68 microM).(ABSTRACT TRUNCATED AT 250 WORDS)     

Potent in vivo but not in vitro inhibition of monoamine oxidase by 3-chloro-alpha-phenylpyrazinemethanol.

3-Chloro-alpha-phenylpyrazinemethanol (3-CPM) inhibited monoamine oxidase (MAO) types A and B in vivo in mouse brain, heart and liver. The inhibition was dose-dependent at doses of 0.3-32 mg/kg i.p. and occurred within 1 h after the compound was injected. 3-CPM was a very weak inhibitor of mouse brain mitochondrial MAO activity in vitro, even when preincubated with the enzyme; MAO-A was inhibited only about 50% at a high concentration of 3-CPM (1 mM), and MAO-B was inhibited even less. After a 10 mg/kg i.p. dose of 3-CPM in mice, both MAO-A and MAO-B were inhibited at day 1, but activity had largely recovered within a few days in brain, liver and heart. 3-CPM at doses of 1, 3, 10 and 32 mg/kg i.p. caused dose-dependent antagonism of the depletion of striatal dopamine and of cortical norepinephrine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 3-CPM is therefore a potent inhibitor of MAO-A and of MAO-B in mice in vivo despite its weak effect on the enzyme in vitro. A metabolite of the drug may be involved in the in vivo effects.     

Formation of the Neurotransmitter Glycine from the Anticonvulsant Milacemide Is Mediated by Brain Monoamine Oxidase B

Milacemide (2-n-pentylaminoacetamide) is a secondary monoamine that in the brain is converted to glycinamide and glycine. This oxidative reaction was suspected to involve the reaction of monoamine oxidase (MAO). Using mitochondrial preparations from tissues that contain MAO-A and -B (rat brain and liver), MAO-A (human placenta), and MAO-B (human platelet and bovine adrenal chromaffin cell), it has been established that mitochondria containing MAO-B rather than MAO-A oxidize (H2O2 production and glycinamide formation) milacemide. The apparent Km (30-90 microM) for milacemide oxidation by mitochondrial MAO-B preparations is significantly lower than that for milacemide oxidation by mitochondrial MAO-A (approximately 1,300 microM). In vitro MAO-B (l-deprenyl and AGN 1135) rather than MAO-A (clorgyline) selectively inhibited the oxidation of milacemide. These in vitro data are matched by ex vivo experiments where milacemide oxidation was compared to oxidation of serotonin (MAO-A) and beta-phenylethylamine (MAO-B) by brain mitochondria prepared from rats pretreated with clorgyline (0.5-10 mg/kg) and l-deprenyl (0.5-10 mg/kg). Furthermore, in vivo experiment demonstrated that l-deprenyl selectively increased the urinary excretion of [14C]milacemide and the total radioactivity with a concomitant decrease of [14C]glycinamide. Such changes were not observed after clorgyline treatment, but were evident only at doses beyond clorgyline selectivity. The present data therefore demonstrate that milacemide is a substrate for brain MAO-B, and its conversion to glycinamide, further transformed to the inhibitory neurotransmitter, glycine, mediated by this enzyme may contribute to its pharmacological activities.     

Inhibition of type A monoamine oxidase by coptisine in mouse brain

The inhibitory effects of coptisine, a protoberberine isoquinoline alkaloid, on type A and type B monoamine oxidase (MAO-A and MAO-B) activities in mouse brain were investigated. Coptisine showed an inhibitory effect on MAO-A activity in a concentration-dependent manner using a substrate kynuramine, but coptisine did not inhibit MAO-B activity. Coptisine exhibited 54.3% inhibition of MAO-A activity at 2 microM. The values of Km and Vmax of MAO-A were 151.9 +/- 0.6 microM and 0.40 +/- 0.03 nmol/min/mg protein, respectively (n=5). Coptisine competitively inhibited MAO-A activity with kynuramine. The Ki value of coptisine was 3.3 microM. The inhibition of MAO-A by coptisine was found to be reversible by dialysis of the incubation mixture. These results suggest that coptisine is a potent reversible inhibitor of MAO-A, and that coptisine functions to regulate the catecholamine content.     

MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice

In mice treated 24 hrs earlier with pargyline (20 mg/kg i.p), both type A and type B monoamine oxidase (MAO-A and MAO-B) were partially inactivated in brain, heart and liver. The abilities of two short-acting, reversible inhibitors of MAO to antagonize that inactivation were compared. Pretreatment with MD 240928 at doses of 10, 20 or 30 mg/kg i.p. antagonized the inactivation of type B MAO but did not alter the inactivation of type A MAO in all three tissues. In contrast, pretreatment with harmaline at a dose of 10 mg/kg i.p. antagonized the inactivation of type A MAO but did not alter the inactivation of type B MAO. Antagonism of the pargyline-induced inactivation is interpreted as being due to the transient selective inhibition of MAO-A by harmaline and of MAO-B by MD 240928, preventing the mechanism-based inactivation of those enzymes by pargyline. The selective protection by harmaline is in agreement with earlier results with that compound in rats; the selective protection by MD 240928 is the first report of selective protection against MAO-B inactivation.     

Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice

Pargyline, an inhibitor of monoamine oxidase type B (MAO-B), did not prevent the depletion of heart norepinephrine 24 hr after a single dose of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in mice. In mice killed 24 hr after the last of 4 daily doses of MPTP, the depletion of dopamine in the striatum and of norepinephrine in the frontal cortex was completely prevented by pargyline, but the depletion of heart norepinephrine was not prevented. These results with pargyline are the same as results obtained earlier with deprenyl, another selective inhibitor of MAO-B. The doses of pargyline and of deprenyl that were used resulted in almost complete inhibition of MAO-B activity (phenylethylamine as substrate) in brain, heart and liver of mice. Deprenyl did not inhibit MAO-A activity (serotonin as substrate) in brain, but pargyline caused some inhibition of MAO-A in brain. In heart and liver, serotonin was oxidized only at about 1/10 the rate of phenylethylamine oxidation, suggesting that MAO-B predominates in these tissues. Both pargyline and deprenyl caused some inhibition of serotonin deamination in heart and liver, suggesting that the oxidation may have been due partly to MAO-B. Experiments with selective MAO inhibitors in vitro showed that only about 20% of the oxidation of serotonin was occurring via MAO-B in heart and liver. The in vitro oxidation of MPTP by MAO in mouse brain, heart and liver was almost completely inhibited by pretreatment with either pargyline or deprenyl. Neither pargyline nor deprenyl had any significant effect on the concentrations of MPTP in brain or heart one-half hr after injection of MPTP into mice. The concentrations of the metabolite, MPP+ (1-methyl-4-phenyl-pyridinium), were markedly reduced in brain and in heart by pretreatment with either pargyline or deprenyl. The data suggest that MPP+ formation, which is necessary for the depletion of brain catecholamines after MPTP injection, may not be necessary for depletion of norepinephrine in heart. Since the oxidation of MPTP in vitro was inhibited more by pargyline or deprenyl pretreatment than was the appearance of MPP+ in vivo, the possibility exists that some MPP+ formation might occur by an enzyme other than MAO.     

The Novel Neuropsychotropic Agent Milacemide Is a Specific Enzyme-Activated Inhibitor of Brain Monoamine Oxidase B

The novel neuropsychotropic agent milacemide hydrochloride (2-n-pentylaminoacetamide HCl) is a highly selective substrate of the B form of monoamine oxidase (EC 1.4.3.4; MAO). Under the in vitro conditions used in the present study, milacemide acts as an enzyme-activated, partially reversible inhibitor of MAO-B. A reversible inhibition of MAO-A activity is also observed at high concentrations. The inhibitory activity of milacemide is significantly greater for MAO-B. In vivo, after single or repeated oral administration, a specific inhibition of MAO-B is apparent in brain and liver, with a lack of inhibition of the MAO-A activity. In contrast to the irreversible inhibitory action of L-deprenyl, the recovery of MAO-B activity in vivo after milacemide administration is significantly faster, a result suggesting that it is a partially reversible inhibitor. The selective inhibitory effect of milacemide for MAO-B in vivo is confirmed by its potentiation of phenylethylamine-induced stereotyped behavior, whereas vasopressor responses to tyramine were not affected. These observations suggest that milacemide could enhance dopaminergic activity in the brain and could be used as therapy for Parkinson's disease in association with L-3,4-dihydroxyphenylalanine.     

Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins

A series of coumarin derivatives (1-22), bearing at the 7-position ether, ketone, ester, carbamate, or amide functions of varying size and lipophilicity, were synthesized and investigated for their in vitro monoamine oxidase-A and -B (MAO-A and -B) inhibitory activities. Most of the compounds acted preferentially as MAO-B inhibitors, with IC(50) values in the micromolar to low-nanomolar range. A structure-activity-relationship (SAR) study highlighted lipophilicity as an important property modulating the MAO-B inhibition potency of 7-substituted coumarins, as shown by a linear correlation (n=20, r(2)=0.72) between pIC(50) and calculated log P values. The stability of ester-containing coumarin derivatives in rat plasma provided information on factors that either favor (lipophilicity) or decrease (steric hindrance) esterase-catalyzed hydrolysis. Two compounds (14 and 22) were selected to investigate how lipophilicity and enzymatic stability may affect in vivo MAO activities, as assayed ex vivo in rat. The most-potent and -selective MAO-B inhibitor 22 (=7-[(3,4-difluorobenzyl)oxy]-3,4-dimethyl-1-benzopyran-2(2H)-one) within the examined series significantly inhibited (>60%) ex vivo rat-liver and striatal MAO-B activities 1 h after intraperitoneal administration of high doses (100 and 300 mumol kg(-1)), revealing its ability to cross the blood-brain barrier. At the same doses, liver and striatum MAO-A was less inhibited in vivo, somehow reflecting MAO-B selectivity, as assessed in vitro. In contrast, the metabolically less stable derivative 14, bearing an isopropyl ester in the lateral chain, had a weak effect on hepatic MAO-B activity in vivo, and none on striatal MAO-B, but, surprisingly, displayed inhibitory effects on MAO-A in both peripheral and brain tissues.     

Design,synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase

In the studied a series novel of lazabemide derivatives were designed, synthesized and evaluated as inhibitors of monoamine oxidase (MAO-A or MAO-B). These compounds used lazabemide as the lead compound, and the chemistry structures were modified by used the bioisostere and modification of compound with alkyl principle. The two types of inhibitors (inhibition of MAO-A and inhibition of MAO-B) were screened by inhibition activity of MAO. In vitro experiments showed that compounds 3a, 3d and 3f had intensity inhibition the biological activity of MAO-A, while compounds 3i and 3m had intensity inhibition the biological activity of MAO-B. It could be seen from the data of inhibition activity experiments in vitro, that the compound 3d was IC₅₀?=?3.12?±?0.05?μmol/mL of MAO-A and compound 3m was IC₅₀?=?5.04?±?0.06?μmol/mL. In vivo inhibition activity experiments were conducted to evaluate the inhibitory activity of compounds 3a, 3d, 3f, 3i and 3m by detecting the contents of 5-HT, NE, DA and activity of MAO-A and MAO-B in plasma and brain tissue. In vivo inhibition activity evaluation results showed that the compounds 3a, 3d, 3f, 3i and 3m had increased the contents of 5-HT, NE and DA in plasma and brain tissues. Meanwhile, the determination results activity of MAO in plasma and brain tissue showed that the compounds 3a, 3d, and 3f had a significant inhibitory effect on the activity of MAO-A, while the compounds 3i and 3m showed inhibitory effect on the activity of MAO-B. This study provided a new inhibitors for inhibiting of MAO activity.